{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T13:37:51Z","timestamp":1774359471472,"version":"3.50.1"},"reference-count":32,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2001,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Residual mediastinal masses are frequently observed in patients with Hodgkin disease (HD) after completed therapy, and the discrimination between active tumor tissue and fibrotic residues remains a clinical challenge. We studied the diagnostic value of metabolic imaging by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in detecting active mediastinal disease and predicting relapse. Twenty-eight HD patients with a residual mediastinal mass of at least 2 cm after initial therapy or after salvage chemotherapy were prospectively assigned to 29 examinations with FDG PET and were evaluated as 29 \u201csubjects.\u201d Patients were monitored for at least 1 year after examination and observed for signs of relapse. Median follow-up was 28 months (range, 16 to 68 months). A PET-negative mediastinal tumor was observed in 19 subjects, of whom 16 stayed in remission and 3 relapsed. Progression or relapse occurred in 6 of 10 subjects with a positive PET, whereas 4 subjects remained in remission. The negative predictive value (negative PET result and remission) at 1 year was 95%, and the positive predictive value (positive PET result and relapse) was 60%. The disease-free survival for PET-negative and PET-positive patients at 1 year was 95% and 40%, respectively. The difference was statistically significant. A negative FDG PET indicates that an HD patient with a residual mediastinal mass is unlikely to relapse before 1 year, if ever. On the other hand, a positive PET result indicates a significantly higher risk of relapse and demands further diagnostic procedures and a closer follow-up.<\/jats:p>","DOI":"10.1182\/blood.v98.10.2930","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T08:46:47Z","timestamp":1027759607000},"page":"2930-2934","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":185,"title":["Thoracic positron emission tomography using18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease"],"prefix":"10.1182","volume":"98","author":[{"given":"Martin R.","family":"Weihrauch","sequence":"first","affiliation":[{"name":"From the Department of Internal Medicine I and Department of Nuclear Medicine, University of Cologne, Germany; Axiogenesis GmbH, Cologne, Germany; and Department of Internal Medicine, Klinikum der Stadt Villingen-Schwenningen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Re","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine I and Department of Nuclear Medicine, University of Cologne, Germany; Axiogenesis GmbH, Cologne, Germany; and Department of Internal Medicine, Klinikum der Stadt Villingen-Schwenningen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klemens","family":"Scheidhauer","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine I and Department of Nuclear Medicine, University of Cologne, Germany; Axiogenesis GmbH, Cologne, Germany; and Department of Internal Medicine, Klinikum der Stadt Villingen-Schwenningen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sascha","family":"Anse\u0301n","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine I and Department of Nuclear Medicine, University of Cologne, Germany; Axiogenesis GmbH, Cologne, Germany; and Department of Internal Medicine, Klinikum der Stadt Villingen-Schwenningen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Dietlein","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine I and Department of Nuclear Medicine, University of Cologne, Germany; Axiogenesis GmbH, Cologne, Germany; and Department of Internal Medicine, Klinikum der Stadt Villingen-Schwenningen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Bischoff","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine I and Department of Nuclear Medicine, University of Cologne, Germany; Axiogenesis GmbH, Cologne, Germany; and Department of Internal Medicine, Klinikum der Stadt Villingen-Schwenningen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heribert","family":"Bohlen","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine I and Department of Nuclear Medicine, University of Cologne, Germany; Axiogenesis GmbH, Cologne, Germany; and Department of Internal Medicine, Klinikum der Stadt Villingen-Schwenningen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju\u0308rgen","family":"Wolf","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine I and Department of Nuclear Medicine, University of Cologne, Germany; Axiogenesis GmbH, Cologne, Germany; and Department of Internal Medicine, Klinikum der Stadt Villingen-Schwenningen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Schicha","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine I and Department of Nuclear Medicine, University of Cologne, Germany; Axiogenesis GmbH, Cologne, Germany; and Department of Internal Medicine, Klinikum der Stadt Villingen-Schwenningen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Diehl","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine I and Department of Nuclear Medicine, University of Cologne, Germany; Axiogenesis GmbH, Cologne, Germany; and Department of Internal Medicine, Klinikum der Stadt Villingen-Schwenningen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Tesch","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine I and Department of Nuclear Medicine, University of Cologne, Germany; Axiogenesis GmbH, Cologne, Germany; and Department of Internal Medicine, Klinikum der Stadt Villingen-Schwenningen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021217321392200_B1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/annonc\/11.suppl_1.S81","article-title":"Treatment of Hodgkin's disease: results and current concepts of the German Hodgkin's Lymphoma Study Group.","volume":"11(suppl 1)","author":"Sieber","year":"2000","journal-title":"Ann Oncol."},{"key":"2020021217321392200_B2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1023\/A:1008283909959","article-title":"Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).","volume":"9","author":"Josting","year":"1998","journal-title":"Ann Oncol."},{"key":"2020021217321392200_B3","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1200\/JCO.1988.6.6.940","article-title":"The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease.","volume":"6","author":"Radford","year":"1988","journal-title":"J Clin Oncol."},{"key":"2020021217321392200_B4","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/1097-0142(19880615)61:12<2439::AID-CNCR2820611208>3.0.CO;2-Q","article-title":"Gallium 67 imaging in monitoring lymphoma response to treatment.","volume":"61","author":"Israel","year":"1988","journal-title":"Cancer."},{"key":"2020021217321392200_B5","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1200\/JCO.1988.6.6.931","article-title":"Residual mass in lymphoma may not be residual disease.","volume":"6","author":"Canellos","year":"1988","journal-title":"J Clin Oncol."},{"key":"2020021217321392200_B6","first-page":"99","article-title":"Mediastinoscopy.","volume":"9","author":"Sarrazin","year":"1992","journal-title":"Rev Mal Respir."},{"key":"2020021217321392200_B7","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1148\/radiology.203.3.9169707","article-title":"Lymphoma: role of whole-body 2-deoxy-2-[F-18] fluoro-D-glucose (FDG) PET in nodal staging.","volume":"203","author":"Moog","year":"1997","journal-title":"Radiology."},{"key":"2020021217321392200_B8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/annonc\/8.suppl_1.S57","article-title":"Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma.","volume":"8(suppl 1)","author":"de Wit","year":"1997","journal-title":"Ann Oncol."},{"key":"2020021217321392200_B9","first-page":"343","article-title":"Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma.","volume":"38","author":"Hoh","year":"1997","journal-title":"J Nucl Med."},{"key":"2020021217321392200_B10","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3109\/10428199909058482","article-title":"Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease.","volume":"34","author":"Wiedmann","year":"1999","journal-title":"Leuk Lymphoma."},{"key":"2020021217321392200_B11","first-page":"266","article-title":"Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.","volume":"86","author":"Jerusalem","year":"2001","journal-title":"Haematologica."},{"key":"2020021217321392200_B12","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1023\/A:1008368330519","article-title":"2-fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution.","volume":"11","author":"Partridge","year":"2000","journal-title":"Ann Oncol."},{"key":"2020021217321392200_B13","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s002590050275","article-title":"Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography.","volume":"25","author":"Stumpe","year":"1998","journal-title":"Eur J Nucl Med."},{"key":"2020021217321392200_B14","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1023\/A:1008486928190","article-title":"Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease.","volume":"9","author":"Bangerter","year":"1998","journal-title":"Ann Oncol."},{"key":"2020021217321392200_B15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00006231-199901000-00004","article-title":"Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma.","volume":"20","author":"Jerusalem","year":"1999","journal-title":"Nucl Med Commun."},{"key":"2020021217321392200_B16","first-page":"235","article-title":"Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using amino-polyether supported nucleophilic substitution.","volume":"27","author":"Hamacher","year":"1986","journal-title":"J Nucl Med."},{"key":"2020021217321392200_B17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/02841851960371P168","article-title":"Long-term follow-up of residual mediastinal masses in treated Hodgkin's disease using MR imaging.","volume":"37","author":"Nyman","year":"1996","journal-title":"Acta Radiol."},{"key":"2020021217321392200_B18","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1148\/radiology.170.2.2911665","article-title":"Residual mediastinal masses in Hodgkin disease: prediction of size with MR imaging.","volume":"170","author":"Nyman","year":"1989","journal-title":"Radiology."},{"key":"2020021217321392200_B19","doi-asserted-by":"crossref","first-page":"721726","DOI":"10.1148\/radiology.156.3.4023233","article-title":"Radiation fibrosis: differentiation from recurrent tumor by MR imaging.","volume":"156","author":"Glazer","year":"1985","journal-title":"Radiology."},{"key":"2020021217321392200_B20","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1200\/JCO.1993.11.11.2273","article-title":"Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma.","volume":"11","author":"Hill","year":"1993","journal-title":"J Clin Oncol."},{"key":"2020021217321392200_B21","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1007\/s002590000340","article-title":"Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears?","volume":"27","author":"Kostakoglu","year":"2000","journal-title":"Eur J Nucl Med."},{"key":"2020021217321392200_B22","first-page":"345","article-title":"Validation of gallium-67-citrate single-photon emission computed tomography in biopsy-confirmed residual Hodgkin's disease in the mediastinum.","volume":"33","author":"Kostakoglu","year":"1992","journal-title":"J Nucl Med."},{"key":"2020021217321392200_B23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00006231-199705000-00004","article-title":"67Ga scintigraphy for the evaluation of recurrences and residual masses in patients with lymphoma.","volume":"18","author":"Setoain","year":"1997","journal-title":"Nucl Med Commun."},{"key":"2020021217321392200_B24","first-page":"288","article-title":"Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma.","volume":"28","author":"Paul","year":"1987","journal-title":"J Nucl Med."},{"key":"2020021217321392200_B25","first-page":"98","article-title":"[Positron-emission tomography with fluorine-18-deoxyglucose in the staging and control of patients with lymphoma. Comparison with clinico- radiologic assessment].","volume":"95","author":"Mainolfi","year":"1998","journal-title":"Radiol Med (Torino)."},{"key":"2020021217321392200_B26","first-page":"24","article-title":"Clinical value of FDG PET for therapy monitoring of malignant lymphoma- -results of a retrospective study in 72 patients.","volume":"38","author":"Cremerius","year":"1999","journal-title":"Nuklearmedizin."},{"key":"2020021217321392200_B27","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/blood.V94.2.429","article-title":"Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.","volume":"94","author":"Jerusalem","year":"1999","journal-title":"Blood."},{"key":"2020021217321392200_B28","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1097\/00006231-199811000-00005","article-title":"Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma.","volume":"19","author":"Cremerius","year":"1998","journal-title":"Nucl Med Commun."},{"key":"2020021217321392200_B29","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1023\/A:1008327127033","article-title":"The role of positron emission tomography (PET) in the management of lymphoma patients.","volume":"10","author":"Zinzani","year":"1999","journal-title":"Ann Oncol."},{"key":"2020021217321392200_B30","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/1097-0142(19830101)51:1<30::AID-CNCR2820510108>3.0.CO;2-6","article-title":"Diffuse thymic hyperplasia following chemotherapy for nodular sclerosing Hodgkin's disease: an immunologic rebound phenomenon?","volume":"51","author":"Shin","year":"1983","journal-title":"Cancer."},{"key":"2020021217321392200_B31","first-page":"888","article-title":"False-positive FDG-PET imaging of the thymus of a child with Hodgkin's disease.","volume":"38","author":"Weinblatt","year":"1997","journal-title":"J Nucl Med."},{"key":"2020021217321392200_B32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1023\/A:1008357126404","article-title":"18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma.","volume":"12","author":"de Wit","year":"2001","journal-title":"Ann Oncol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/98\/10\/2930\/1678051\/h8220102930.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/98\/10\/2930\/1678051\/h8220102930.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T18:26:04Z","timestamp":1581531964000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/98\/10\/2930\/176589\/Thoracic-positron-emission-tomography"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11,15]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2001,11,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v98.10.2930","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2001,11,15]]}}}